Statera Biopharma
Statera Biopharma
STAB
OTC
0.00
USD
0.00%
About
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532.
The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 790 |
| Three Month Average Volume | 168.3K |
| High Low | |
| Fifty-Two Week High | 0.0376 USD |
| Fifty-Two Week Low | 0 USD |
| Fifty-Two Week High Date | 18 Oct 2023 |
| Fifty-Two Week Low Date | 08 Aug 2024 |
| Price and Volume | |
| Current Price | 0.0006 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.34% |
| Thirteen Week Relative Price Change | -6.57% |
| Twenty-Six Week Relative Price Change | -9.05% |
| Fifty-Two Week Relative Price Change | 59.61% |
| Year-to-Date Relative Price Change | -15.55% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 0.00% |
| Twenty-Six Week Price Change | 0.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | 100.00% |
| Year-to-Date Price Change | 0.00% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.04419 USD |
| Book Value Per Share (Most Recent Quarter) | -0.20182 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.3499 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.40887 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.39875 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.04235 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.07338 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.90088 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.72217 USD |
| Normalized (Last Fiscal Year) | -0.98201 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.90088 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.72217 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.90088 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.72217 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.05578 USD |
| Cash Per Share (Most Recent Quarter) | 0.00997 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.89429 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.8168 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.24266 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -751 |
| Cash Flow Revenue (Trailing Twelve Months) | -331 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,490.94% |
| Pretax Margin (Last Fiscal Year) | -6,850.87% |
| Pretax Margin (5 Year) | -2,026.20% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 67.16% |
| Gross Margin (Trailing Twelve Months) | 70.27% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -6,544.21% |
| Operating Margin (Trailing Twelve Months) | -2,363.75% |
| Operating Margin (5 Year) | -1,893.51% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -6,850.87% |
| Net Profit Margin (Trailing Twelve Months) | -2,490.94% |
| Net Profit Margin (5 Year) | -2,026.20% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 183.47% |
| Revenue Growth (3 Year) | -15.82% |
| Revenue Change (Trailing Twelve Months) | 1,459.13% |
| Revenue Per Share Growth | -33.28% |
| Revenue Growth (5 Year) | 9.32% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 77.96% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 85.83% |
| EPS Change (Trailing Twelve Months) | -71.12% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 5.9M |
| Net Debt (Last Fiscal Year) | 13.2M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -28,376,250 |
| Free Cash Flow (Trailing Twelve Months) | -12,194,440 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -7 |
| Net Interest Coverage (Trailing Twelve Months) | -4 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -867.48% |
| Return on Assets (Trailing Twelve Months) | -165.83% |
| Return on Assets (5 Year) | -325.12% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -287.51% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -2,951.58% |
| Return on Investment (Trailing Twelve Months) | -234.87% |
| Return on Investment (5 Year) | -6,108.38% |